Related Experiment Video
Updated: Jul 1, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
RNA profiling of MS brain tissues
J Kinter1, T Zeis, N Schaeren-Wiemers
1Neurobiology, Department of Biomedicine and Neurology, University Hospital Basel, Basel, Switzerland.
RNA profiling of postmortem brain tissue using microarrays helps identify gene expression changes in multiple sclerosis (MS). This approach aids in discovering biomarkers and understanding MS pathophysiology.
Area of Science:
- Neuroscience
- Genomics
- Molecular Biology
Background:
- Postmortem human brain tissue analysis is crucial for understanding neurological diseases.
- Multiple Sclerosis (MS) research lacks sufficient diagnostic and prognostic biomarkers.
- Gene expression profiling offers insights into disease mechanisms.
Purpose of the Study:
- To review critical parameters for RNA profiling in MS brain tissues.
- To summarize findings from microarray studies on differential gene expression in MS.
- To highlight the utility of RNA profiling in MS research.
Main Methods:
- Utilizing microarray technology for RNA profiling.
- Analyzing gene expression data from postmortem MS brain samples.
- Discussing critical parameters for successful RNA profiling.
Main Results:
- Microarray studies have identified specific gene expression alterations in MS brain tissues.
- RNA profiling is a valuable tool for investigating MS molecular pathomechanisms.
- Differential gene expression analysis reveals potential disease-specific changes.
Conclusions:
- RNA profiling of MS brain tissue is a powerful method for molecular investigation.
- This technique contributes to the identification of potential biomarkers and drug targets.
- Understanding gene expression changes is key to advancing MS research and treatment.
More Related Videos
11:49Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
Published on: August 28, 2021
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016